We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
After absorption in gastrointestinal tract, the drug metabolize slowly in vivo, then gradually hydrolyze into nicotinic acid and inositol and plays role through the two products. It can ease and persistently relax peripheral vascular, improve the abnormal lipid metabolism, dissolve fibrin protein, thrombolytic and anticoagulant. It can be adjunctive therapy of hyperlipoprotememia, coronary heart disease and various peripheral vascular spasm (such as arteriosclerosis obliterans, Raynaud's disease, migraine etc.).
【Quality standard】：
ITEM
Standard
Result
Appearance:
White or White-like powder
White powder
Identify:
A B C conformed
Pass
Clear:
< BY6
Pass
Heavy Metal:
< 10ppm
Pass
Content:
98.0-101.0% Art No. ALA0029A
98.0-101.0%
Loss on drying:
< 0.5%
0.18%
CL:
< 350ppm
< 100ppm
Free Nicotinate acid:
< 0.8ml/g
0.20ml/g
Relative substance:
Conformed
Pass
Sulfate Ash:
< 0.1%
0.02%
Acetone:
Conformed
Pass
Total Plate Count:
< 1000cfu/g
< 100/g
Molds:
< 100cfu/g
< 10/g
Yeast:
< 100/g
< 10/g
E-Coli:
Negative
Negative
Salmonella:
Negative
Negative
Package:25kg/ paper drum or based on customer requirement.
Application:
In Clinic it can be adjunctive therapy of hyperlipidemia, coronary heart disease, peripheral vascular disorders (such as arteriosclerosis obliterans, Raynaud's disease, frostbite, vascular migraine etc.) adjuvant therapy.
Audited Supplier
Pharma Sources Insight JANUARY 2024
